Work

Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy

Year: 2021

Type: article

Source: Annals of Allergy Asthma & Immunology

DOI: 10.1016/j.anai.2021.03.003

Authors: Elena Goleva, Taras Lyubchenko, Lukas Kraehenbuehl, Mario E. Lacouture, Donald Y.M. Leung, Jeffrey A. Kern

Institutions: National Jewish Health, Memorial Sloan Kettering Cancer Center, Swim Across America, Weill Cornell Medicine

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases

Awards: Identification of pathways to mitigate Immune-Related Adverse Events with Cancer Immunotherapy , G2665966410, G4102770861, G6403603385, G8589387000, G9000003249, Cancer Center Support Grant, SEAL (Stopping Atopic dermatitis and ALlergy) Study: Prevent allergy by enhancing the skin barrier

OpenAlex ID: W3134715681

FWCI: 3.012

Cites: 115

Cited by: 58

Related to: 10